Trials / Completed
CompletedNCT03657446
A Study in Healthy Subjects to Investigate Whether Administration of Clazosentan Can Affect Normal Heart Function
Randomized, Double-blind (for Clazosentan), Placebo- and Moxifloxacincontrolled, 3-way Cross-over Phase 1 Study to Assess the Effect of Two Intravenous Doses of Clazosentan on the QTc Interval Duration in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Idorsia Pharmaceuticals Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The study will investigate whether administration of clazosentan can affect normal heart function in healthy subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clazosentan | Continuous i.v. infusion of 20 mg/h or 60 mg/h of clazosentan for 3 h |
| DRUG | Placebo | Matching placebo infusion |
| DRUG | Moxifloxacin | Film-coated tablet containing 400 mg moxifloxacin |
Timeline
- Start date
- 2018-09-18
- Primary completion
- 2018-10-26
- Completion
- 2018-10-26
- First posted
- 2018-09-05
- Last updated
- 2018-11-20
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT03657446. Inclusion in this directory is not an endorsement.